✦ LIBER ✦

Potential new agents in the prophylaxis and treatment of chemotherapy-induced emesis

✍ Scribed by J. Herrstedt

Book ID: 117657188
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 75 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)00062-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of dexamethasone and ondanset

Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy

✍ Jones, A.L.; Hill, A.S.; Cunningham, D.; Soukop, M.; Hutcheon, A.W.; Cassidy, J. 📂 Article 📅 1991 🏛 The Lancet 🌐 English ⚖ 728 KB

Chemotherapy-induced nausea and vomiting

Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment

✍ Karin Jordan; Christoph Kasper; Hans-Joachim Schmoll 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 263 KB

Comparison of three tropisetron-containi

Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea

✍ S. Drechsler; U. Bruntsch; J. Eggert; J. Grote-Kiehn; H. Gosse; M. Bangerter; D. 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 175 KB

IV granisetron VS IV granisetron plus IV

IV granisetron VS IV granisetron plus IV dexamethasone in the prophylaxis of emesis induced by cytotoxic chemotherapy

✍ Carmicheal, J; Bessell, E; Hutcheon, A 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Comparison of ondansetron with dexametha

Comparison of ondansetron with dexamethasone and domperidone in the prophylaxis of non-cisplatin chemotherapy induced emesis refractory to dexamethasone

✍ Evans, Christopher; Stein, Robert C.; Davenport, Joanna; Dougherty, Lisa; Carrut 📂 Article 📅 1991 🏛 Elsevier Science ⚖ 285 KB

Treatment of chemotherapy-induced emesis

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3receptor antagonists

✍ P. J. Hesketh 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 730 KB

Paul J. Hesketh the optimal use of the 5-HT3 antagonists and their integration into clinical practice remain unanswered and are the appropriate focus for additional study.